Abstract 3982
Background
A special role in the tumour progression is played by heterogeneous components of the microenvironment of tumours, premetastatic tumour niches, influencing which seems likely to change the disease course. Our purpose was to analyze some characteristics of the local cellular immunity in metastatic GC.
Methods
33 GC patients aged 30-80 years were divided into 2 groups: group 1 – M0, non-metastatic GC, n = 17, mean age 61.7±8.9 years (G2 – 11, G3 – 6 patients); group 2 – M1, GC with peritoneal and omentum metastases, n = 16, mean age 58.7±11.5 years (G2 – 7, G3 – 5, G4 - 3 patients). Tumours (T), peritumoral tissues (PT), omentum (O) and peritoneum (P) tissues were studied. Lymphocytes were determined by flow cytometry using FACSCantoII (BD) and T-, B-, NK antibody panels; quantitative content of DN (CD3+CD4-CD8-), DP (CD3+CD4+CD8+) T lymphocytes and regulatory (T-regs) T cells (CD4+CD25+CD127dim) was studied.
Results
Patients with M1 GC demonstrated increased CD3+ lymphocytic infiltration of T, PT, O and P tissues. IRI in M1 O was significantly higher than in M0 (1.95±0.3 vs 0.7±0.2), being similar in other tissues. Levels of DN lymphocytes were lower in O of M1, compared to M0 (7.7±2.5 vs 15.7±5.6, p ≤ 0.05). Contents of NK cells, NKT lymphocytes significantly decreased in O of M1 patients, compared to M0 (3.3≤1.1 vs 14.0≤2.3 and 1.7±0.5 vs 3.8±0.8, respectively). Higher levels of NKT lymphocytes were registered in M1 PT, compared to M0 (3.3±1.1 vs 1.3±0.4), as well as lower levels of NK cells in T (2.3±0.9 vs 5.33±0.2). Percentage of Treg lymphocytes in P and O were significantly lower in M1 than in M0 (respectively, 6.9±1.5 vs 12.6±4.9 and 5.9±1.3 vs 12.6±4.9). Higher amount of B lymphocytes was registered in all tissues of M1 patients, compared to M0, maximal in O (13.1±3.3 vs 3.4±1.5), T (23.5±5.1 vs 17.2±2.3) and P (8.2±3.4 vs 3.5±1.2), while in PT it was lower (15.7±4.2 vs 43.7±4.5).
Conclusions
GC metastasis to the omentum and peritoneum is characterized by a change in their immunological features – a decrease in the tissue level of NK and NKT lymphocytes, a loss in the prevalence of CD3+CD8+ due to an increase in the number of CD3+CD4+ cells, and an increase in the level of CD19 + (B2) lymphocytes. This probably contributes to the appearance of metastatic lesions in these organs in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3875 - Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5793 - Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets.
Presenter: Ashley Horne
Session: Poster Display session 2
Resources:
Abstract
3185 - Utilization Pattern of Bone Targeting Agents in Patients with Solid Tumor in Taiwan, Hong Kong and Korea
Presenter: Shi Jie Lai
Session: Poster Display session 2
Resources:
Abstract
3705 - Clinico-pathological Features and Prognosis of Patients with Pregnancy Associated Breast Cancer – A Matched Case Control Study
Presenter: Ruyan Zhang
Session: Poster Display session 2
Resources:
Abstract
1421 - TRYbeCA-2: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
4119 - CONTESSA TRIO: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus 3 Different PD-(L)1 Inhibitors in Patients with Metastatic Triple-Negative Breast Cancer (TNBC) and Tesetaxel Monotherapy in Elderly Patients with HER2- Metastatic Breast Cancer (MBC)
Presenter: Sara Tolaney
Session: Poster Display session 2
Resources:
Abstract
4545 - Bintrafusp alfa (M7824) and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (TNBC)(NCT03579472)
Presenter: Jennifer Litton
Session: Poster Display session 2
Resources:
Abstract
3340 - Effectiveness of Olaparib Plus Trastuzumab in HER2[+], BRCA–mutated (BRCAm) or Homologous Recombination Deficient (HRD) Advanced Breast Cancer (ABC) patients (pts). The OPHELIA Study
Presenter: José Enrique Alés-Martínez
Session: Poster Display session 2
Resources:
Abstract
1113 - RIBOB : A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease
Presenter: Cindy Kenis
Session: Poster Display session 2
Resources:
Abstract
4025 - RIbociclib plus Goserelin with Hormonal Therapy versus physician Choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer – RIGHT Choice study
Presenter: Nagi El Saghir
Session: Poster Display session 2
Resources:
Abstract